Acute graft-versus-host disease (aGVHD) is a common complication of allogeneic hematopoietic stem cell transplantation (alloHCT) and is a major cause of morbidity and mortality. Systemic steroid therapy is the first-line treatment for aGVHD, although about half of patients will become refractory to treatment. As the number of patients undergoing alloHCT increases, developing safe and effective treatments for aGVHD will become increasingly important, especially for those whose disease becomes refractory to systemic steroid therapy. This paper reviews current treatment options for patients with steroid-refractory aGVHD and discusses data from recently published clinical studies to outline emerging therapeutic strategies.

中文翻译：

---

类固醇难治性急性移植物抗宿主病的治疗和未满足的需求。

急性移植物抗宿主病（aGVHD）是同种异体造血干细胞移植（alloHCT）的常见并发症，是发病率和死亡率的主要原因。全身类固醇治疗是aGVHD的一线治疗，尽管约有一半的患者会变得难以治疗。随着接受alloHCT的患者数量的增加，为aGVHD开发安全有效的治疗方法将变得越来越重要，特别是对于那些疾病变得无法接受全身性类固醇治疗的患者。本文回顾了目前对类固醇难治性aGVHD患者的治疗方案，并讨论了最近发表的临床研究数据，概述了新兴的治疗策略。